The Use of Baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice Perspective



De Beaurepaire, Renaud, Sinclair, Julia MA, Heydtmann, Mathis, Addolorato, Giovanni, Aubin, Henri-Jean, Beraha, Esther M, Caputo, Fabio, Chick, Jonathan D, de la Selle, Patrick, Franchitto, Nicolas
et al (show 16 more authors) (2019) The Use of Baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice Perspective. FRONTIERS IN PSYCHIATRY, 9 (JAN). 708-.

[thumbnail of Baclofen A clinical prospective R1 clean.docx] Text
Baclofen A clinical prospective R1 clean.docx - Author Accepted Manuscript

Download (137kB)

Abstract

Alcohol use disorder (AUD) is a brain disorder associated with high rates of mortality and morbidity worldwide. Baclofen, a selective gamma-aminobutyric acid-B (GABA-B) receptor agonist, has emerged as a promising drug for AUD. The use of this drug remains controversial, in part due to uncertainty regarding dosing and efficacy, alongside concerns about safety. To date there have been 15 randomized controlled trials (RCTs) investigating the use of baclofen in AUD; three using doses over 100 mg/day. Two additional RCTs have been completed but have not yet been published. Most trials used fixed dosing of 30-80 mg/day. The other approach involved titration until the desired clinical effect was achieved, or unwanted effects emerged. The maintenance dose varies widely from 30 to more than 300 mg/day. Baclofen may be particularly advantageous in those with liver disease, due to its limited hepatic metabolism and safe profile in this population. Patients should be informed that the use of baclofen for AUD is as an "off-label" prescription, that no optimal fixed dose has been established, and that existing clinical evidence on efficacy is inconsistent. Baclofen therapy requires careful medical monitoring due to safety considerations, particularly at higher doses and in those with comorbid physical and/or psychiatric conditions. Baclofen is mostly used in some European countries and Australia, and in particular, for patients who have not benefitted from the currently used and approved medications for AUD.

Item Type: Article
Uncontrolled Keywords: GABA-B, baclofen, alcohol use disorder, efficacy, safety
Depositing User: Symplectic Admin
Date Deposited: 26 Feb 2019 09:47
Last Modified: 19 Jan 2023 01:01
DOI: 10.3389/fpsyt.2018.00708
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3033448